These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27830384)

  • 1. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.
    Ebina K; Kashii M; Hirao M; Hashimoto J; Noguchi T; Koizumi K; Kitaguchi K; Matsuoka H; Iwahashi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Sep; 35(5):571-580. PubMed ID: 27830384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
    Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N
    J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Kaneshiro S; Noguchi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Jan; 35(1):91-98. PubMed ID: 26762133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
    Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.
    Sánchez A; Brun LR; Salerni H; Costanzo PR; González D; Bagur A; Oliveri B; Zanchetta MB; Farías V; Maffei L; Premrou V; Mansur JL; Larroudé MS; Sarli MA; Rey P; Ulla MR; Pavlove MM; Karlsbrum S; Brance ML
    J Osteoporos; 2016; 2016():8738959. PubMed ID: 27579211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study.
    Park CH; Yoo JI; Choi CH; Suh YS
    BMC Musculoskelet Disord; 2020 Nov; 21(1):751. PubMed ID: 33189148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
    Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.
    Cosman F; Oates M; Betah D; Timoshanko J; Wang Z; Ferrari S; McClung MR
    J Bone Miner Res; 2024 Sep; 39(9):1268-1277. PubMed ID: 39041711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
    Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
    Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
    Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
    Oue T; Shimizu T; Asano T; Shimodan S; Ishizu H; Arita K; Iwasaki N
    Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Clin Nutr ESPEN; 2022 Apr; 48():267-274. PubMed ID: 35331501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.